Pantoprazole A Proton Pump Inhibitor

被引:21
|
作者
Dias, Luis Moreira
机构
[1] Médico Gastroenterologista,
关键词
GASTROESOPHAGEAL-REFLUX DISEASE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; A BLOOD-CONCENTRATION; 40 MG PANTOPRAZOLE; MAINTENANCE THERAPY; DOUBLE-BLIND; PHARMACOKINETIC INTERACTION; GASTROINTESTINAL LESIONS; EROSIVE ESOPHAGITIS; ORAL PANTOPRAZOLE;
D O I
10.2165/1153121-S0-000000000-00000
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pantoprazole is a proton pump inhibitor (PPI) that binds irreversibly and specifically to the proton pump, thereby reducing gastric acid secretion. Pantoprazole has a relatively long duration of action compared with other PPIs, and a lower propensity to become activated in slightly acidic body compartments. To date, no drug-drug interactions have been identified with pantoprazole in numerous interaction Studies. Overall, in the short-term (8-10 weeks) initial treatment of gastro-oesophageal reflux disease (a condition that occurs when the reflux of gastric contents causes troublesome symptoms and/or complications) and long-term (6-24 months) maintenance therapy, oral pantoprazole 20 or 40 mg/day demonstrated similar efficacy to omeprazole, lansoprazole and esomeprazole and greater efficacy than histamine type 2 receptor antagonists. Pantoprazole is also effective in treating and preventing NSAID-related gastric and gastroduodenal injury. The optimal adult oral dose for gastric acid-related disorders is pantoprazole 40 mg once daily. Although data are limited, pantoprazole 20 or 40 mg/day was effective and well tolerated in the treatment of acid-related disorders in children and adolescents. Pantoprazole was also well tolerated in adults With acid-related disorders in short- and long-term Studies. Thus, pantoprazole is a valuable agent for the management of acid-related disorders.
引用
收藏
页码:3 / 12
页数:10
相关论文
共 50 条
  • [41] Aspirin and Proton Pump Inhibitor
    Risser, Nancy
    Murphy, Mary
    NURSE PRACTITIONER, 2005, 30 (06): : 55 - 56
  • [42] Use of the Proton Pump Inhibitor Pantoprazole to Modify the Distribution and Activity of Doxorubicin: A Potential Strategy to Improve the Therapy of Solid Tumors
    Patel, Krupa J.
    Lee, Carol
    Tan, Qian
    Tannock, Ian F.
    CLINICAL CANCER RESEARCH, 2013, 19 (24) : 6766 - 6776
  • [43] Proton Pump Inhibitor Pantoprazole Modulates Intestinal Microbiota and Induces TLR4 Signaling and Fibrosis in Mouse Liver
    Assalin, Heloisa B.
    Gabriel De Almeida, Kelly Cristiane
    Guadagnini, Dioze
    Santos, Andrey
    Teixeira, Caio J.
    Bordin, Silvana
    Rocha, Guilherme Z.
    Saad, Mario J. A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [44] Administering a Soda Beverage With the Hepatitis C Treatment Sofosbuvir/Velpatasvir and the Proton-Pump Inhibitor Pantoprazole: A Case Report
    Stark, Jennifer E. E.
    Montgomery, Clarice M. M.
    JOURNAL OF PHARMACY PRACTICE, 2024, 37 (04) : 1011 - 1014
  • [45] Proton pump inhibitor pantoprazole inhibits gastric cancer metastasis via suppression of telomerase reverse transcriptase gene expression
    Zhang, Bin
    Ling, Tingsheng
    Zhaxi, Panduo
    Cao, Yu
    Qian, Liping
    Zhao, Dian
    Kang, Wei
    Zhang, Weijie
    Wang, Lei
    Xu, Guifang
    Zou, Xiaoping
    CANCER LETTERS, 2019, 452 : 23 - 30
  • [46] Augmentation of myelopoiesis in a murine host bearing a T cell lymphoma following in vivo administration of proton pump inhibitor pantoprazole
    Vishvakarma, Naveen Kumar
    Singh, Sukh Mahendra
    BIOCHIMIE, 2011, 93 (10) : 1786 - 1796
  • [48] Synthesis of a DOTA (Gd3+)-conjugate of proton-pump inhibitor pantoprazole for gastric wall imaging studies
    Maharvi, Ghulam M.
    Bharucha, Adil E.
    Fauq, Abdul H.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (09) : 2808 - 2811
  • [49] The proton pump inhibitor pantoprazole disrupts protein degradation systems and sensitizes cancer cells to death under various stresses
    Yu Cao
    Min Chen
    Dehua Tang
    Hongli Yan
    Xiwei Ding
    Fan Zhou
    Mingming Zhang
    Guifang Xu
    Weijie Zhang
    Shu Zhang
    Yuzheng Zhuge
    Lei Wang
    Xiaoping Zou
    Cell Death & Disease, 9
  • [50] The proton pump inhibitor pantoprazole disrupts protein degradation systems and sensitizes cancer cells to death under various stresses
    Cao, Yu
    Chen, Min
    Tang, Dehua
    Yan, Hongli
    Ding, Xiwei
    Zhou, Fan
    Zhang, Mingming
    Xu, Guifang
    Zhang, Weijie
    Zhang, Shu
    Zhuge, Yuzheng
    Wang, Lei
    Zou, Xiaoping
    CELL DEATH & DISEASE, 2018, 9